NASDAQ: CORT · Pharmaceuticals
Corcept Therapeutics (CORT) fair value: undervalued or overvalued?
As of 31 Oct 2026, Faircurve's model values Corcept Therapeutics (CORT) at $75.67 a share. The stock last closed at $81.93, which puts the model's fair value 7.6% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 3 Nov 2026. Corcept Therapeutics Incorporated.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $80.56 to $75.67 (-6.1%). Analysts cut their next-twelve-month EBITDA estimates: part of the move.
What the model makes of itThe price of $81.93 is 7.6% above it: Fairly valued, on a medium evidence grade.
What's nextReports on 4 Nov 2026. Options expiring after the report price a move of about 11% either way. The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give CORT?
The calibrated range for CORT over 63 trading days is $61.03 to $117.66. It sits around the last close, and its width comes from the volatility that CORT's own options imply (99% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $56.01 to $101.25. In 42% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Corcept Therapeutics Incorporated (CORT) is a pharmaceutical firm founded in 1998 and headquartered in Menlo Park, California. It is dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric conditions.
Faircurve's model puts the fair value at $75.67 a share, the midpoint of 2,000 simulations, as at 31 Oct 2026. The previous run, on 24 Oct 2026, gave $80.56, so the fair value moved -6.1%. The model's own reason is that analysts cut their next-twelve-month EBITDA estimates, which is part of the move. The calibrated range over 63 trading days runs from $59.48 to $121.42. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices across 6,661 past valuations. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade looks at input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.
The model's overall quality score for Corcept is 62 out of 100, a composite of six factors. Balance sheet scores 100, with net debt to EBITDA at -3.53x against a peer median of 4.02x. Earnings quality scores 90, with free cash flow to net income at 1.95x. Growth quality scores 83, with trailing revenue growth at 12.8% against a peer median of 7.1%. Profitability scores 15, with ROIC at 1.1% against a peer median of 2.7%. The model compares the company with AptarGroup, Inc. (ATR) and Bruker Corporation (BRKR).
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CORT report earnings, and how has the stock reacted?
Corcept Therapeutics's next earnings report is scheduled for 4 Nov 2026. Companies can move their dates.
Options prices on 4 Nov 2026 imply a move of about 11.2% in either direction through the nearest expiry, about 15 days out, a window that includes the report. That is the size the market is pricing, not a direction. CORT's 30 day implied volatility works out to about 28.6% over one month.
Around its last 4 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CORT's last 8 reports, ignoring direction, was 2.4%.
Earlier reports are left out: the options record is on a different share basis.
What the options market has priced for a month's move in CORT
How does CORT score on business quality?
Corcept Therapeutics's overall quality score is 62 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 15 | 1.1%ROIC | 2.7% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 90 | 1.95xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 83 | 12.8%Revenue growth, trailing | 7.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 78 | 1.1%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -3.53xNet debt / EBITDA | 4.02x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 50 | 7.1 ptsEBITDA margin downside volatility, 5y | 9.7 pts |
How does CORT compare with similar companies?
The companies in pharmaceuticals closest to Corcept Therapeutics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| PBH Prestige Consumer Healthcare Inc. | $49.54 | $45.28 | -8.6% | Low evidence grade |
| CYTK Cytokinetics, Incorporated | $62.31 | $52.67 | -15.5% | Low evidence grade |
| ATR AptarGroup, Inc. | $142.31 | $132.22 | -7.1% | Fairly valued |
| BRKR Bruker Corporation | $56.50 | $63.61 | +12.6% | Fairly valued |
| HQY HealthEquity, Inc. | $102.03 | $111.17 | +9.0% | Low evidence grade |
| ARWR Arrowhead Pharmaceuticals, Inc. | $59.53 | $49.37 | -17.1% | Data under review |
| UHS Universal Health Services, Inc. | $177.13 | $284.60 | +60.7% | Gap wider than 60% |
| TGTX TG Therapeutics, Inc. | $60.75 | $70.94 | +16.8% | Low evidence grade |
What the comparable companies' multiples alone would give for CORT, the peer-implied price, is $43.57 a share on this run. The fair value weighs that against the company's own multiple.
Corcept Therapeutics at a glance
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric.
- Market value
- $8.8B
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Revenue expected, next twelve months
- $1.5B
- Consensus revenue growth, next fiscal year
- +46.0%
- Analysts with estimates
- 4
- Beta to the US market
- 1.91
- First valued by Faircurve
- 11 Jul 2026
At the close of 3 Nov 2026, 52.1% of the 1,081 graded US stocks the model covers traded below the model's fair value. CORT was not among them.
How the fair value is worked out: the model prices Corcept Therapeutics on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for CORT was $80.56. As of 31 Oct 2026 it is $75.67, a change of -6.1%. Analysts cut their next-twelve-month EBITDA estimates: part of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Corcept Therapeutics's valuation
Is Corcept Therapeutics stock undervalued or overvalued?
On Faircurve's model, CORT reads as Fairly valued as of 31 Oct 2026. The model's fair value is $75.67 a share against a last close of $81.93, a gap of -7.6%.
What is CORT's fair value?
$75.67 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $56.01 to $101.25.
What price range does the model give CORT?
$61.03 to $117.66 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Corcept Therapeutics report earnings next?
The next report is scheduled for 4 Nov 2026. Companies can move their dates.
How much has CORT moved on past earnings reports?
Across its last 8 reports the median two session move was 2.4%, ignoring direction. The largest was +25.6% around the report of 29 Jul 2026.
How confident is the model in this valuation?
The model's evidence grade for CORT is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CORT
The model holds no idea open on CORT today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CORT with their outcomes. A free account is enough.